Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124


Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Boche D, Denham N, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Sep;120(3):369-84. doi: 10.1007/s00401-010-0719-5. Epub 2010 Jul 15. Review.


Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review.

Uro-Coste E, Russano de Paiva G, Guilbeau-Frugier C, Sastre N, Ousset PJ, da Silva NA, Lavialle-Guillotreau V, Vellas B, Delisle MB.

Clin Neuropathol. 2010 Jul-Aug;29(4):209-16. Review.


Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.

Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Jul;120(1):13-20. doi: 10.1007/s00401-010-0705-y. Epub 2010 Jun 9.


A single ascending dose study of bapineuzumab in patients with Alzheimer disease.

Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203. doi: 10.1097/WAD.0b013e3181c53b00.


Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.

Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.


Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Cribbs DH.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. Review.


A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.


Cervical lymph nodes are found in direct relationship with the internal carotid artery: significance for the lymphatic drainage of the brain.

Clapham R, O'Sullivan E, Weller RO, Carare RO.

Clin Anat. 2010 Jan;23(1):43-7. doi: 10.1002/ca.20887.


Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.

Weller RO, Preston SD, Subash M, Carare RO.

Alzheimers Res Ther. 2009 Oct 12;1(2):6. doi: 10.1186/alzrt6.


Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.

Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4501-6. doi: 10.1073/pnas.0813404106. Epub 2009 Feb 25.


Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy.

Weller RO, Boche D, Nicoll JA.

Acta Neuropathol. 2009 Jul;118(1):87-102. doi: 10.1007/s00401-009-0498-z. Epub 2009 Feb 22. Review.


Threats to the mind: aging, amyloid, and hypertension.

Iadecola C, Park L, Capone C.

Stroke. 2009 Mar;40(3 Suppl):S40-4. doi: 10.1161/STROKEAHA.108.533638. Epub 2008 Dec 8. Review.


Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.


Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH.

J Neuroinflammation. 2008 Sep 29;5:42. doi: 10.1186/1742-2094-5-42.


Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA.

Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.


Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice.

Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, Grimm J, Pons J, Morgan D.

J Neuroimmune Pharmacol. 2008 Sep;3(3):187-97. doi: 10.1007/s11481-008-9114-6. Epub 2008 Jul 8.


Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.

J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008.


Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.

Xu F, Vitek MP, Colton CA, Previti ML, Gharkholonarehe N, Davis J, Van Nostrand WE.

J Neurosci. 2008 May 14;28(20):5312-20. doi: 10.1523/JNEUROSCI.1042-08.2008.


A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.

Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D.

J Neurosci. 2008 Apr 2;28(14):3555-66. doi: 10.1523/JNEUROSCI.0208-08.2008.


Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

Weller RO, Subash M, Preston SD, Mazanti I, Carare RO.

Brain Pathol. 2008 Apr;18(2):253-66. doi: 10.1111/j.1750-3639.2008.00133.x. Review.

Items per page

Supplemental Content

Write to the Help Desk